HIGHLIGHTS
- who: Yan Li and colleagues from the This is a multi-centered, randomized, double-blind, placebo-controlled clinical trialReporting of the study results will follow the CONSORT statement [21]. Subjects will be enrolled at four hospitals in mainland China: First Affiliated Hospital of Heilongjiang University of Chinese Medicine, First Affiliated Hospital of Harbin Medical University, Fourth Affiliated Hospital of Harbin Medical University, and First Affiliated Hospital of Guangzhou Medical School. This study has been approved by the ethics committee of the First Affiliated Hospital of Heilongjiang University of Chinese Medicine ( HZYLL-012). Informed consent will be obtained . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.